Exicure to Present at 2019 International Oligonucleotide and Peptide Conference
September 17 2019 - 4:30PM
Business Wire
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, announced today that its chief operating officer, Dr.
Matthias Schroff, will give a company presentation titled,
“Multitargeting Spherical Nucleic Acids: Advantages &
Applications,” on Wednesday, September 18, 2019 at 11:40 am GMT at
the 2019 International Oligonucleotide and Peptide Conference. The
presentation will be made in the Caplus Room of the Ramada Plaza
Hotel in Milan.
About Exicure, Inc. Exicure, Inc. is a clinical-stage
biotechnology company developing therapeutics for immuno-oncology,
inflammatory diseases and genetic disorders based on our
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure's lead program is in a Phase 1b/2 trial in
patients with advanced solid tumors. Exicure is based outside of
Chicago, IL and in Cambridge, MA. www.exicuretx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190917005273/en/
MacDougall Karen Sharma 781-235-3060 ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024